Moviprep Patent Expiration

Moviprep is a drug owned by Salix Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 01, 2024. Details of Moviprep's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169381 Colon cleansing compositions and methods
Sep, 2024

(a month from now)

Active
US7658914 Colon cleansing compositions
Sep, 2024

(a month from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Moviprep's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Moviprep's generic, the next section provides detailed information on ongoing and past EP oppositions related to Moviprep patents.

Moviprep's oppositions filed in EPO

Moviprep has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 12, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP03758361A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP03758361A May, 2009 Teva Pharmaceutical Industries LTD. Opposition procedure closed


US patents provide insights into the exclusivity only within the United States, but Moviprep is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Moviprep's family patents as well as insights into ongoing legal events on those patents.

Moviprep's family patents

Moviprep has patent protection in a total of 22 countries. It's US patent count contributes only to 14.8% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Moviprep.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Moviprep's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 01, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Moviprep Generics:

Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate is the generic name for the brand Moviprep. 1 company has already filed for the generic of Moviprep. Check out the entire list of companies who have already received approval for Moviprep's generic

How can I launch a generic of Moviprep before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Moviprep's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Moviprep's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Moviprep -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch 27 Nov, 2007 1 25 Jan, 2012 01 Sep, 2024 Eligible




About Moviprep

Moviprep is a drug owned by Salix Pharmaceuticals Inc. Moviprep uses Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate as an active ingredient. Moviprep was launched by Salix Pharms in 2006.

Market Authorisation Date:

Moviprep was approved by FDA for market use on 02 August, 2006.

Active Ingredient:

Moviprep uses Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate as the active ingredient. Check out other Drugs and Companies using Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate ingredient

Dosage:

Moviprep is available in for solution form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM FOR SOLUTION Prescription ORAL